NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company's mission to revolutionize antiviral treatment through its nanoviricide platform. Dr. Diwan highlighted progress of lead drug candidate NV-387, explaining how nanoviricides are designed to prevent viral escape, function independently of patient immune status, and offer broad-spectrum potential across patient populations from infants to geriatrics.
During the interview, Dr. Diwan noted that NV-387 has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles. The candidate has completed a Phase I clinical trial with no reported adverse events, and a Phase II clinical trial for NV-387 targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance. This positions NV-387 as a potential empirical therapy for acute respiratory and other viral infections with an estimated market opportunity exceeding $17 billion by 2030.
The company's nanoviricide technology is based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc., with NanoViricides holding a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc., as detailed on their corporate website at https://www.nanoviricides.com.
NanoViricides' business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. The company holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of numerous human viral diseases including Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, and certain Coronaviruses.
Beyond NV-387, the company is developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The company's other advanced drug candidate is NV-HHV-1 for the treatment of Shingles, though the company cannot project an exact date for filing an IND for any of its drugs because of dependence on external collaborators and consultants.
The company's platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if initial research is successful. As with any drug development efforts, there can be no assurance at this time that any of the company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development, nor that successful results against coronavirus in lab settings will lead to successful clinical trials or a successful pharmaceutical product.
The full press release containing this information is available at https://ibn.fm/EqHoVA, and the latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. The interview highlights the potential of nanoviricide technology to address significant unmet medical needs in antiviral treatment, particularly given the broad-spectrum capabilities demonstrated by NV-387 across multiple virus families and its progress toward Phase II clinical trials.
